The 99th Annual Meeting of the Japanese Pharmacological Society

Chair:Hisaharu Yamada(Corporate Strategy Division, Mediford Corporatio), Teisuke Takahashi(Taisho Pharmaceuticals Co., Ltd.)

Drug development typically requires enormous costs and a period of more than 10 years, from the start of research and development to product launch and sales. During the drug development process, research and development is often abandoned due to various factors, including safety and pharmacokinetic issues and insufficient efficacy. For this reason, success rate is low and difficulty remains extremely high, just as it has in the past. However, pharmaceutical companies spare no effort to increase the success rate. At this symposium, researchers from leading pharmaceutical companies in Japan will talk about their efforts to introduce new in vitro evaluation methods through the introduction of New Approach Methods (NAMs), as well as their efforts to integrate rapidly advancing artificial intelligence (AI) and data science into actual research workflows.